91̽��

Popular 91̽�� articles

Swedish Cancer Foundation
An article on the TAT groups work with targeted alpha therapy of ovarian cancer, brought about the fellowship awarded to Emma Aneheim during 2019 by the same foundation. In Swedish 

91̽�� Spotlight - Fred Hutch News
The Fred Hutchinson Cancer Research Center published a popular science news article on their web-page "Fine-tuning radioimmunotherapy with an alpha-emitting radionuclide" in April 15, 2013, concerning a collaborative work with Tom Bäck.

Research Media
Innovative immunotherapy. Lars Jacobsson and Ragnar Hultborn. International Innovation, May 2012, (Research Media, UK, pp 114-116).

Onkologi i Sverige
Konform strålterapi på cellnivå med alfaradioligander. The article (in Swedish) is found via the link below. The article was published in the 5^th issue at pages 66-71, 2011.

Dagens Medicin
A summary of the article (in Swedish) is found via the link below. The whole article was published on the 7^th of June, 2007.

Forskning & Framsteg
A summary of the article (in Swedish) is found via the link below. The whole article was published in number 8 of the journal, 2007.

��ö�ٱ���ǰ�����-�ʴDz��ٱ��
A summary of the article (in Swedish) is found via the link below. The whole article was published on the 1^rst of March, 2005.

PhD Theses

Anna Gustafsson-Lutz, Chemist.
Development of targeted alpha therapy with Bi-213 and At-211 for the treatment of disseminated cancer - Synthesis and evaluation of pretargeting components and radioimmunoconjugates. Institute of Clinical 91̽��s. Sahlgrenska Academy, University 91̽��. 2016.

Elin Cederkrantz, Physicist.
Pharmacokinetics and dosimetry in intraperitoneal radioimmunotherapy with At-211. Institute of Clinical 91̽��s, Sahlgrenska Academy, University 91̽��. 2014.

Karin Magnander, Physicist.
Formation and Repair of Complex DNA Damage Induced by Ionizing Radiation Institute of Clinical 91̽��s. Sahlgrenska Academy. University 91̽��. 2013.

Sofia Frost, Chemist.
Pretargeting agents and 211At-labeled effector molecules. Synthesis and preclinical evaluation for pretargeted alpha-radioimmunotherapy. Institute of Clinical 91̽��s. Sahlgrenska Academy. University 91̽��. 2012.  See .

Kristina Claesson, Physicist.
Radiobiological effects of alpha-particles from Astatine-211. From DNA damage to cell death. Institute of Clinical 91̽��s, Sahlgrenska Academy, University 91̽��. 2011.

Tom Bäck, Biomedical Scientist.
Alpha-radioimmunotherapy with At-211. Evaluation and imaging of normal tissues and tumors.
Institute of Clinical 91̽��s, Sahlgrenska Academy. University 91̽��. 2011.

Jörgen Elgqvist, Physicist.
Astatine-211 radioimmunotherapy of ovarian cancer – therapeutic efficacy, myelotoxicity, and radiation dosimetry in an animal model. Institute of Clinical 91̽��s, Sahlgrenska Academy. University 91̽��. 2006.

Sture Lindegren, Chemist.
Astatine-211 and iodine conjugates: Radiohalogenation and preclinical pharmacokinetics for targeted and pretargeted radioimmunotherapy, Department of Nuclear Chemistry, Chalmers University of Technology 2002.

Håkan Andersson, Physician.
Radioimmunotherapy of experimental ovarian cancer with astatine-211 – a model for consolidation treatment in women. Department of Oncology, University 91̽��, 2000.

Stig Palm, Physicist.
In vitro effects and microdosimetry of astatine-211 for tumour therapy. Institute of Clinical 91̽��s. Sahlgrenska Academy, University 91̽��. 1999.

MSc theses

19. Johan Almblad
Pretargeted radioimmunotherapy using the inverse diels alder addition between tetrazine and trans-cyclooctene Supervisor: Sture Lindegren, Emma Aneheim, 2017.

18. John Apelman
Production of an Avidin Conjugated Antibody Pretargeting Agent Supervisor: Sture Lindegren, Emma Aneheim, 2015.

17. Tierra Duffield
Synthesis and Quality Control of Radiohalogenated PSMA Inhibitors for Targeted Therapy of Prostate Cancer Supervisor: Sture Lindegren, Emma Aneheim, 2015.

16. David Wadsten
Fc-gammaR in Alpha-radioimmunotherapy: Work up of a head to head in vivo comparison of F(ab)2 fragments with intact IgG MX35 Supervisor: Per Albertsson, 2013.

15. Besart Rexhaj
Initial development of voxel dose kernel dosimetry in MATLAB for alpha particles using Alpha Camera imaging of tissue samples Supervisors: Tom Bäck and Stig Palm, 2013.

14. Jenny Halleröd
Shelf life of "epsilon-Lysyl-3-(Trimethylstannyl) Benzamide Immunoconjugates and Poly-L-Lysine Conjugates. Supervisor: Sture Lindegren, Emma Aneheim, 2013.

13. Johnny Kallin
Development of a dosimetric model for alpha-particle irradiation with ²¹³Bi and an in vitro experiment to assess complex DNA damage in human diploid fibroblasts. Supervisors: Kecke Elmroth, Karin Magnander, and Jörgen Elgqvist, 2011.

12. Daniela Markoscan
Evaluation of Ligand Tracer Grey Instrument. Supervisor: Sture Lindegren, 2009.

11. Emil Boström
¹²⁵I-labelling of TRP-receptor ligand for prostate cancer therapy. Supervisor: Sture Lindegren, 2008.

10. Jens Zimmerman
Activity determination of the alpha-emitting radionuclide ²²⁵Ac. Supervisor: Stig Palm, 2007.

9. Sofia Frost
Synthesis and evaluation of pretargeting and effector molecules for pretargeted radioimmunotherapy. Supervisor: Sture Lindegren, 2006.

8. Maria Ohlsson
Optimising a method for visualising gammaH2AX-foci after irradiation with X-ray and Astatine-211. Supervisors: Kecke Elmroth and Lars Jacobsson, 2006.

7. Karin Magnander
The use of pulsed field gel electrophoresis, measuring double-strand breaks and clustered damage after exposure to ionizing radiation of different beam qualities. Supervisors: Kecke Elmroth and Lars Jacobsson, 2005.

6. Leif Jonasson
A study of the binding kinetics of MX-35 on OVCAR-3 cancer cells using ²¹¹At. Supervisors: Gunnar Skarnemark and Lars Jacobsson, 2003.

5. Jonas Häller
A study of the antibody MX-35 labeled with ²¹¹At on OVCAR-3 cells for cancer therapy. Supervisors: Gunnar Skarnemark, Lars Jacobsson and Allan Emrén, 2003.

4. Kristina Claesson
Distribution and quantification of DNA double-strand breaks in a human cells irradiated with X-rays and alpha-particles from ²¹¹At. Supervisor: Kecke Elmroth, 2003.

3. Lisa Hansson
Binding kinetics of ¹²⁵I labeled monoclonal antibodies evaluated in vitro with a radiation detector system. Supervisor: Lars Jacobsson, 2002.

2. Karin Bengtsson
Utvärdering av internalisering av radioaktivt märkta antikroppar och av antikroppar i pretargetingsystem. Supervisor: Sture Lindegren, 2000.

1. Charlotta Johansson
Activity measurements of ²¹¹At Supervisor: Lars Jacobsson, 1999.

Articles, Books and Chapters

2020

84. Lindegren S, Albertsson P, Bäck T, Jensen H, Palm S, Aneheim E.Realizing Clinical Trials With Astatine-211: The Chemistry Infrastructure. 

2019

83. Aneheim E, Palm S, Jensen H, Ekberg C, Albertsson P, Lindegren S. Towards elucidating the radiochemistry of astatine – Behavior in chloroform. 

82. Denk C, Wilkovitsch M, Aneheim E, Herth M, Jensen H, Lindegren S, Mikula H. Multifunctional clickable reagents for rapid bioorthogonal astatination and radio‐crosslinking. 

81. Dekempeneer Y, Bäck T, Aneheim E, Jensen H, Puttemans J, Xavier C, Keyaerts M, Palm S, Albertsson P, Lahoutte T, Caveliers V, Lindegren S, D'Huyvetter M, Labeling of anti-HER2 nanobodies with astatine-211: Optimization and the effect of different coupling reagents on their in vivo behaviour. 

80. Hallqvist A, Bergmark K, Bäck T, Andersson H, Dahm-Kähler P, Johansson M, Lindegren S, Jensen H, Jacobsson L, Hultborn R, Palm S, Albertsson P. Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations. 

2018

79. Palm S, Bäck T, Lindegren S, Hultborn R, Jacobsson L, Albertsson P. Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes. 

2017

78. Gustafsson-Lutz A, Bäck T, Aneheim E, Hultborn R, Palm S, Jacobsson L, Morgenstern A, Bruchertseifer F, Albertsson P, Lindegren S. Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model. 

77. Bäck T, Chouin N, Lindegren S, Kahu H, Jensen H, Albertsson P, Palm S. Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with 211At-MX35-F(ab′)2: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival   

76. Levan K, Mehryar M, Mateoiu C, Albertsson P, Bäck T, Sundfeldt K.
Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. 

75. Gustafsson-Lutz A, Bäck T, Aneheim A, Palm S, Morgenstern A, Bruchertseifer F, Albertsson P, Lindegren S. Biotinylated and Chelated Poly-L-Lysine as Effector for Pretargeting in Cancer Therapy and Imaging. 

2016

74. Aneheim E, Gustafsson A, Albertsson P, Bäck T, Jensen H, Palm S, Svedhem S, Lindegren S. Synthesis and Evaluation of Astatinated N‑[2-(Maleimido)ethyl]-3- (trimethylstannyl)benzamide Immunoconjugates. 

73. Palm S, Bäck T, Haraldsson B, Jacobsson L, Lindegren S, Albertsson P. Biokinetic Modeling and Dosimetry for Optimizing Intraperitoneal Radioimmunotherapy of Ovarian Cancer Microtumors. 

Artiklar, böcker och kapitel 1998-2015

 

2015

72. Frost S H, Miller B W, Bäck T A, Santos E B, Hamlin D K, Knoblaugh S E, Frayo S L, Kenoyer A L, Storb R, Press O W, Wilbur D S, Pagel J M, Sandmaier B M. α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation, 

71. Cederkrantz E, Andersson H, Bernhardt P, Bäck T, Hultborn R, Jacobsson L, Jensen H, Lindegren S, Ljungberg M, Magnander T, Palm S, Albertsson P. Absorbed Doses and Risk Estimates of 211At-MX35 F(ab’)2 in Intraperitoneal Therapy of Ovarian Cancer Patients, 

70. Aneheim E, Albertsson P, Bäck T, Jensen H, Palm S, Lindegren S.
Automated astatination of biomolecules – a stepping stone towards multicenter clinical trials, 

69. Green J D, Shadman M, Jones J C, Frayo S L, Kenoyer A L, Hylarides M D, Hamlin D K, Wilbur S, Balkan E R, Lin Y, Miller B W, Frost S H L, Gopal A K, Orozco J J, Gooley T A, Laird K L, Till B G, Bäck T, Sandmaier B M, Pagel J M, Press O W. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model, 

68. Lindegren S, Andrade L N S, Bäck T, Machado C M L, Horta B B, Buchpiguel C, Moro A M, Okamoto O K, Jacobsson L, Cederkrantz E, Washiyama K, Aneheim E, Palm S, Jensen H, Tuma M C B, Chammas R, Hultborn R, Albertsson P. Binding Affinity, Specificity and comparative Biodistribution of the Parental Murine Monoclonal antibody MX35 (anti-NaPi2b) and its Humanized Version Rebmab200, 

67. Aneheim E, Halleröd J, Albertsson P, Jensen H, Holgersson S, Lindegren S. Shelf-life of ϵ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, a precursor for 211At labeling of antibodies

66. Aneheim E, Foreman M, Jensen H, Lindegren S, N-[2-(maleimido)ethyl]-3-(trimethylstannyl)benzamide, a molecule for radiohalogenation of proteins and peptides,

65. Aneheim E, Jensen H, Albertsson P, Lindegren S. Astatine-211 labeling: a study towards automatic production of astatinated antibodies,

2014

64. Eriksson S. E, Elgström E, Bäck T, Ohlsson T, Jensen H, Nilsson R, Lindegren S, Tennvall J. Sequential Radioimmunotherapy with ¹⁷⁷Lu and ²¹¹At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma Model. 

63. Lindegren S, Jensen H, Jacobsson L. A radio-high-performance liquid chromatography dual-flow cell gamma-detection system for on-line radiochemical purity and labeling efficiency determination. 

62. Elgqvist J, Frost S, Pouget J-P, Albertsson P. The potential and hurdles of targeted alpha therapy – clinical trials and beyond.  doi: 10.3389/fonc.2013.00324

2013

61. Frost S H L, Santos E B, Miller B W, Bäck T A, Hamlin D K, Wilbur S, Kenoyer A L, Frayo S L, Press O W, Storb R, Sandmaier B M, Pagel J M. Anti-CD45 Monoclonal Antibody (MAb) Dose Optimization For Astatine-211 (211At)-Radioimmunotherapy (RIT) Of Relapsed Non-Hodgkin Lymphoma (NHL) In a Canine Model. 

60. Orozco JJ, Bäck T, Kenoyer A, Balkin ER, Hamlin DK, Wilbur DS, Fisher DR, Frayo SL, Hylarides MD, Green DJ, Gopal AK, Press OW, Pagel JM. Anti-CD45 radioimmunotherapy using ²¹¹At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.

59. Chouin N, Lindegren S, Frost S, Jensen H, Albertsson P, Hultborn R, Palm S, Jacobsson L, Bäck T. Ex vivo activity quantification at the cellular scale using the Alpha Camera-technique. 

58. Eriksson SE, Bäck T, Elgström E, Jensen H, Nilsson R, Lindegren S, Tennvall J. Successful radioimmunotherapy of established syngeneic rat colon carcinoma with ²¹¹At-mAb.,  doi:10.1186/2191-219X-3-23

57. Frost SH, Bäck T, Chouin N, Hultborn R, Jacobsson L, Elgqvist J, Jensen H, Albertsson P, Lindegren S. Comparison of ²¹¹At-PRIT and ²¹¹At-RIT of ovarian microtumors in a nude mouse model. 

56. Danielsson A, Claesson K, Parris TZ, Nemes S, Helou K, Elmroth K, Elgqvist J, Jensen H, Hultborn R. Differential gene expression in human fibroblasts after alpha-particle emitter 211At compared with 60Co irradiation. 

2012

55. Choiun N, Lindegren S, Jensen H, Albertsson P, Bäck T. Quantification of activity by alpha-camera imaging and small-scale dosimetry within ovarian carcinoma micrometastases treated with targeted alpha therapy. 

54. Magnander K and Elmroth K. Biological consequences of formation and repair of complex DNA damage. 

53. Cederkrantz E, Angenete E, Bäck T, Falk P, Haraldsson B, Ivarsson ML, Jensen H, Lindegren S, Hultborn R, Jacobsson L. Evaluation of effects on the peritoneum after intraperitoneal alpha-radioimmunotherapy with ²¹¹At. 

52. Gustafsson A, Bäck T, Elgqvist J, Jacobsson L, Hultborn R, Albertsson P, Morgenstern A, Bruchertseifer F, Jensen H and Lindegren S. Comparison of therapeutic efficacy and biodistribution of ²¹³Bi- and ²¹¹At-labeled monoclonal antibody MX35 in an ovarian cancer model. 

51. Elgqvist J, Lindegren S and Albertsson P. Intraperitoneal radionuclide therapy – Clinical and pre-clinical considerations. Book chapter in Ovarian Cancer - Book 2. Publisher: InTech. ISBN 978-953-307-810-6. 

2011

50. Frost HLS, Bäck T, Choiun N, Jensen H, Hultborn R, Jacobsson L and Lindegren S. In vivo distribution of avidin-conjugated MX35 and ²¹¹At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal alpha-radioimmunotherapy. 

49. Pagel JM, Kenoyer AL, Bäck T, Hamlin DK, Wilbur DS, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N, Orozco J, Shenoi J, Lin Y, Gopal AK, Green DJ, Appelbaum FR, Press OW. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. 

48. Claesson K, Magnander K, Kahu H, Lindegren S, Hultborn R, Elmroth K. RBE of alpha-particles from ²¹¹At for complex DNA damage and cell survival in relation to cell cycle position. 

47. Elgqvist J. Editorial; The Magic-Bullet: Moving the concept towards reality - Part II

46. Palm S, Elgqvist J and Jacobsson L. Patient-specific alpha-particle dosimetry. 

45. Lindegren S and Frost S. Pretargeted radioimmunotherapy with alpha-particle emitting radionuclides. 

44. Chouin N and Bardies M. Alpha-particle microdosimetry.

43. Olafsen T, Elgqvist J, and Wu A. Protein targeting constructs in alpha therapy. 

42. Elgqvist J. Editorial; The Magic-Bullet: Moving the concept towards reality - Part I. 

41. Claesson K, Magnander K, Kahu H, Lindegren S, Hultborn R, and Elmroth K. RBE of alpha-particles from At-211 for complex DNA damage and cell survival in relation to cell cycle position. 

2010

40. Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T, Lin Y, Fisher DR, Gopal AK, Green DJ, Press OW. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.   

39. Magnander K, Hultborn R, Claesson K, and Elmroth K. Clustered DNA damage in irradiated human diploid fibroblasts: influence of chromatin organization. 

38. Bäck T and Jacobsson L. The Alpha Camera: A quantitative CCD-based digital autoradiography technique for high resolution bioimaging of alpha particles ex-vivo.

37. Sgouros G, Roeske J, McDevitt M, Palm S, Allen B, Fisher D, Brill A, Song H, Howell R, and Akabani G. MIRD Pamphlet No. 22: Radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.

36. Elgqvist J, Ahlberg D, Andersson H, Jensen H, Johansson BR, Kahu H, Olsson M, and Lindegren S. Intraperitoneal alpha-radioimmunotherapy of advanced ovarian cancer in nude mice using different high specific activities. 

35. Elgqvist J, Johansson BR, Partheen K, and Danielsson A. Tumor cure probability during alpha-RIT of ovarian cancer with different radiation sensitivity. 

34. Elgqvist J, Hultborn R, Lindegren S, and Palm S. Ovarian cancer: Background and clinical perspectives. .

33. Elgqvist J. Astatine-211 radioimmunotherapy of ovarian cancer – Therapeutic efficacy, myelotoxocity and radiation dosimetry in an animal model. .

32. Frost S, Jensen H, and Lindegren S. In vitro evaluation of avidin antibody pretargeting using ²¹¹At-labeled and biotinylated poly-L-lysine as effector molecule. 

2009

31. Bäck T, Haraldsson B, Hultborn R, Jensen H, Johansson ME, Lindegren S, and Jacobsson L. Glomerular filtration rate after alpha-radioimmunotherapy with ²¹¹At- MX35-F(ab´)2: A long-term study of renal function in nude mice. 

30. Elgqvist J, Andersson H, Jensen H, Kahu H, Lindegren S, Warnhammar E, and Hultborn R. Repeated intraperitoneal alpha-radioimmunotherapy of ovarian cancer. 

29. Elgqvist J, Andersson H, Haglund E, Jensen H, Kahu H, Lindegren S, Warnhammar E, and Hultborn R. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities. 

28. Andersson H, Cederkrantz E, Bäck T, Divgi C, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H, Lindegren S, Palm S, and Hultborn R. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of ²¹¹At-MX35 F(ab´)2 – a phase I study. 

2008

27. Lindegren S, Frost S, Bäck T, Haglund E, Elgqvist J, and Jensen H. Direct procedure for the production of ²¹¹At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate. 

2007

26. Claesson K, Stenerlöw B, Jacobsson L, and Elmroth K. Relative biological effectiveness of the alpha-particle emitter ²¹¹At for double-strand break induction in human fibroblasts. 

25. Palm A, Bäck T, Claesson I, Danielsson A, Elgqvist J, Frost S, Hultborn R, Jensen H, Lindegren S, and Jacobsson L. Therapeutic efficacy of astatine-211–labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. 

2006

24. Elgqvist J, Andersson H, Back T, Claesson I, Hultborn R, Jensen H, Lindegren S, Olsson M, Palm S, Warnhammar E, and Jacobsson L. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with ²¹¹At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity. 

23. Elgqvist J, Andersson H, Bernhardt P, Back T, Claesson I, Hultborn R, Jensen H, Johansson BR, Lindegren S, Olsson M, Palm S, Warnhammar E, and Jacobsson L. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with ²¹¹At-MX35 F(ab')2. 

22. Elgqvist J, Andersson H, Back T, Claesson I, Hultborn R, Jensen H, Johansson BR, Lindegren S, Olsson M, Palm S, Warnhammar E, and Jacobsson L. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. 

2005

21. Elgqvist J, Andersson H, Back T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, and Jacobsson L. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with ²¹¹At-labeled monoclonal antibody MX35. 

20. Bäck T, Andersson H, Divgi CR, Hultborn R, Jensen H, Lindegren S, Palm S, and Jacobsson L. ²¹¹At Radioimmunotherapy of subcutaneous human ovarian cancer xenografts: Evaluation of relative biologic effectiveness of an alpha-emitter in vivo. 

19. Elgqvist J, Bernhardt P, Hultborn R, Karlsson B, Lindegren S, Warnhammar E, and Jacobsson L. Myelotoxicity and RBE of ²¹¹At-conjugated monoclonal antibodies compared with ^99mTc-conjugated monoclonal antibodies and ⁶⁰Co irradiation in nude mice. 

2004

18. Palm S, Humm JL, Rundqvist R, and Jacobsson L. Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion. .

17. Ballangrud A, Yang W, Palm S, Enmon R, Borchardt P, Pellegrini V, McDevitt M, Scheinberg D, and Sgouros G. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.

2003

16. Palm S, Enmon R Jr, Matei C, Kolbert K, Xu S, Zanzonico P, Finn R, Koutcher J, Larson S, and Sgouros G. Pharmacokinetics and biodistribution of ⁸⁶Y-Trastuzumab for ⁹⁰Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. 

15. Andersson H, Elgqvist J, Horvath G, Hultborn R, Jacobsson L, Jensen H, Karlsson B, Lindegren S, and Palm S. Astatine-211 labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. 

14. Lindegren S, Karlsson B, Jacobsson L, Andersson H, Hultborn R, and Skarnemark G. At-211 labelled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-L-and poly-D-Lysine as multicarriers. 

13. Palm S, Bäck T, Claesson I, Delle U, Hultborn R, Lindegren S, and Jacobsson L. Single-cell irradiation from At-211 labeled C215 monoclonal antibody: improved estimates of radiosensitivity from measurements on cellular uptake and retention. . 2003;23:1219–1222.

2002

12. Lindegren S, Andersson H, Jacobsson L, Back T, Skarnemark G, and Karlsson B. Synthesis and biodistribution of ²¹¹At-labeled, biotinylated, and charge-modified poly-L-lysine: evaluation for use as an effector molecule in pretargeted intraperitoneal tumor therapy.  

2001

11. Lindegren S, Bäck T, and Jensen H. Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. 

10. Lindegren S, Andersson H, Bäck T, Jacobsson L, Karlsson B, and Skarnemark G. High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labelling of N-succinimidyl 3-(trimethylstannyl) benzoate. 

9. Andersson H, Palm S, Lindegren S, Bäck T, Jacobsson L, Leser G, and Horvath G. Comparison of the therapeutic efficacy of ²¹¹At- and ¹³¹I-labelled monoclonal antibody Mov18 in nude mice with intraperitoneally growth of human ovarian cancer. . 2001;21:409–412.

8. Palm S and Jacobsson L. Dosimetrical considerations in astatine-211 radioimmunotherapy in therapeutic applications of radiopharmaceuticals. Proceedings of an international seminar held in Hyderbad, India, 18–22 January, 1999. IAEA-Tecdoc 1228. .

2000

7. Palm S, Andersson H, Bäck T, Claesson I, Delle U, Hultborn R, Jacobsson L, Köpf I, and Lindegren S. Cell growth kinetics of two human cancer cell lines irradiated with astatine-211 and gamma-radiation. . 2000;20:1807–1812.

6. Andersson H, Lindegren S, Bäck T, Jacobsson L, Leser G, and Horvath G. The curative and palliative potential of the monoclonal antibody Mov18 labelled with ²¹¹At in nude mice with intraperitoneally growing ovarian cancer xenografts – a long term study. 

5. Palm S, Andersson H, Bäck T, Claesson I, Delle U, Hultborn R, Jacobsson L, Köpf I and Lindegren S. In vitro effects of free ²¹¹At, ²¹¹At-albumin, and ²¹¹At-monoclonal antibody compared to external photon irradiation on two human cancer cell lines. . 2000;20:1005–1012.

4. Andersson H, Lindegren S, Bäck T, Jacobsson L, Leser G, and Horvath G. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing ²¹¹At-labelled monoclonal antibody Mov18. . 2000:20:459–462.

1999

3. Andersson H, Lindegren S, Bäck T, Jacobsson L, Leser G, and Horvath G. Biokinetics of the monoclonal antibodies Mov 18, OV 185 and OV 197 labelled with ¹²⁵I according to the m-MeATE method of the iodogen method in nude mice with ovarian cancer xenografts. 

1998

2. Palm S, Bäck T, Claesson I, Delle U, Hultborn R, Jacobsson L, Köpf I, and Lindegren S. Effects of the alpha-particle emitter At-211 and low-dose-rate gamma-radiation on the human cell line Colo-205 as studied with a growth assay. . 1998;18:1671–1676.

1. Lindegren S, Skarnemark G, Jacobsson L, and Karlsson B. Chloramine-T in high-specific-activity radioiodination of antibodies using N-succinimidyl-3-(trimethylstannyl)benzoate as a